Travere Therapeutics, Inc. (TVTX) Stock
TVTX Key Statistics
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
CEO: Eric Dube. Company website
TVTX — Frequently Asked Questions
What is the TVTX stock price today?
Travere Therapeutics, Inc. (TVTX) trades at $41.55, up 35.35% on the day, as of Sep 20, 2026 15:01 UTC.
What is Travere Therapeutics, Inc.'s market cap?
Travere Therapeutics, Inc. has a market capitalisation of $3.83B, calculated from the live TVTX share price and shares outstanding.
What is the P/E ratio of TVTX?
TVTX has no meaningful price-to-earnings ratio: Travere Therapeutics, Inc. lost $0.60 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Travere Therapeutics, Inc. make?
Travere Therapeutics, Inc. generated revenue of $490.73M over the trailing twelve months, which puts the stock at 7.81 times sales.
What is the 52-week range for TVTX?
TVTX has traded between $22.06 and $68.73 over the past 52 weeks, and the last price is 39.5% below that high.
Is Travere Therapeutics, Inc. profitable?
No. Travere Therapeutics, Inc. is loss-making, with a net margin of -10.24% over the trailing twelve months.
What is the analyst price target for TVTX?
Wall Street analysts rate TVTX Buy, with an average price target of $51.50, 23.9% above the current price.
What sector is Travere Therapeutics, Inc. in?
Travere Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Travere Therapeutics, Inc.?
Eric Dube is the chief executive of Travere Therapeutics, Inc., which employs 385 people.
Where can I track TVTX in real time?
QFI Terminal shows TVTX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See TVTX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open TVTX in Terminal See plans